Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
1. An antibody or antigen binding fragment thereof that binds to tumor necrosis factor ligand 1A (TL1A), wherein the antibody or antigen binding fragment thereof comprises: (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 104 and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 201.
2. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment thereof is a humanized antibody or humanized antigen binding fragment.
3. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment comprises a human IgG1 heavy chain constant region.
4. The antibody or antigen binding fragment of claim 3 , wherein the heavy chain constant region comprises one amino acid deletion.
5. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment comprises a human kappa light chain constant region.
6. An antibody that binds to tumor necrosis factor ligand 1A (TL1A), wherein the antibody comprises: (a) a heavy chain comprising the amino acid sequence of SEQ ID NO: 505 and (b) a light chain comprising the amino acid sequence of SEQ ID NO: 514.
7. The antibody of claim 6 , wherein the heavy chain comprises one amino acid deletion.